Rebekah N. Thompson
Researcher
Also affiliated: University of Arkansas Medical Center (2025)
Unknown Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Rebekah N. Thompson's research focuses on antimicrobial resistance, particularly in Gram-negative bacteria. Her work investigates the mechanisms by which bacteria develop resistance to critical antibiotics, such as cefiderocol. A recent publication details how insertion sequence IS Aba36 in the siderophore receptor pirA is associated with treatment-emergent cefiderocol resistance in carbapenem-resistant *Acinetobacter baumannii*. Thompson also explores alternative therapeutic strategies, as indicated by a publication on the use of aztreonam–avibactam with eravacycline for a tibial septic non-union caused by NDM-producing *Enterobacter cloacae*. Her scholarship metrics include an h-index of 2, with 2 total publications and 26 total citations. She collaborates with researchers at the University of Arkansas for Medical Sciences, including Ryan K. Dare and Jacob M. Keck, with whom she shares two publications.
Metrics
- h-index: 2
- Publications: 2
- Citations: 27
Selected Publications
-
Use of Aztreonam–Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae (2025)
-
Treatment-emergent cefiderocol resistance in carbapenem-resistant <i>Acinetobacter baumannii</i> is associated with insertion sequence IS <i>Aba36</i> in the siderophore receptor <i>pirA</i> (2024)
Collaboration Network
Top Collaborators
- Treatment-emergent cefiderocol resistance in carbapenem-resistant <i>Acinetobacter baumannii</i> is associated with insertion sequence IS <i>Aba36</i> in the siderophore receptor <i>pirA</i>
- Use of Aztreonam–Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae
- Treatment-emergent cefiderocol resistance in carbapenem-resistant <i>Acinetobacter baumannii</i> is associated with insertion sequence IS <i>Aba36</i> in the siderophore receptor <i>pirA</i>
- Use of Aztreonam–Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae
- Treatment-emergent cefiderocol resistance in carbapenem-resistant <i>Acinetobacter baumannii</i> is associated with insertion sequence IS <i>Aba36</i> in the siderophore receptor <i>pirA</i>
- Treatment-emergent cefiderocol resistance in carbapenem-resistant <i>Acinetobacter baumannii</i> is associated with insertion sequence IS <i>Aba36</i> in the siderophore receptor <i>pirA</i>
- Treatment-emergent cefiderocol resistance in carbapenem-resistant <i>Acinetobacter baumannii</i> is associated with insertion sequence IS <i>Aba36</i> in the siderophore receptor <i>pirA</i>
- Treatment-emergent cefiderocol resistance in carbapenem-resistant <i>Acinetobacter baumannii</i> is associated with insertion sequence IS <i>Aba36</i> in the siderophore receptor <i>pirA</i>
- Treatment-emergent cefiderocol resistance in carbapenem-resistant <i>Acinetobacter baumannii</i> is associated with insertion sequence IS <i>Aba36</i> in the siderophore receptor <i>pirA</i>
- Treatment-emergent cefiderocol resistance in carbapenem-resistant <i>Acinetobacter baumannii</i> is associated with insertion sequence IS <i>Aba36</i> in the siderophore receptor <i>pirA</i>
- Use of Aztreonam–Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae
- Use of Aztreonam–Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae
Similar Researchers
Based on overlapping research topics